Ebenbuild developed based on patient data personalized simulation models of lungs, so-called digital twins. These are designed to predict airflow, acting forces, and tissue expansion within the lungs and calculate digital biomarkers from this. This helps physicians accurately assess the effects of ventilation on the individual patient and make informed treatment decisions.
With its technology, the startup aims to improve treatment outcomes for artificial ventilation in intensive care patients with acute respiratory distress syndrome (ARDS). ARDS is a severe and often fatal pulmonary complication that typically occurs as a result of other diseases. Worldwide, more than 3 million people are affected each year, and around 40 percent of those affected die from lung failure. Since the beginning of the coronavirus pandemic, the numbers have continued to rise.
“We are convinced that after years of preparation and more than 15 years of international top-level research, we can now consider clinical use with our product,”
explains Ebenbuild Managing Director and Founder Kei MüllerWith the new financial resources, the startup, founded in 2019, is now driving forward the further development of its prototypes in order to ultimately achieve market readiness and approval as a medical device, Müller continued.
“Ebenbuild develops an outstanding technology”
"Ebenbuild is developing an outstanding technology that combines physics-based simulation and AI methods. The founders' years of expertise in biomechanics, artificial intelligence, software engineering, and research make Ebenbuild an attractive partner for a steadily growing number of renowned clinical institutions. We share the company's long-term vision and are pleased to support Ebenbuild on its further journey,"
explained George Ried, one of the two managing directors of Bayern Kapital.
"Ebenbuild addresses a very relevant problem in artificial ventilation in intensive care units. Not only patients would benefit from this solution, but also physicians and hospitals, as it would reduce lung damage, shorten hospital stays, and thus lower costs. We look forward to supporting the team on its further journey,"
supplemented Niels Sharman, Investment Manager at High-Tech Gründerfonds.
